The aim of this study was to evaluate the efficacy and feasibility of intensified consolidation therapy employing fludarabine and ARA-C in cycle 1 and intermediate-dose ARA-C (IDAC) in cycles 2 through 4, in elderly acute myeloid leukemia (AML) patients and to analyze the effects of pegfilgrastim on the duration of neutropenia, overall toxicity, and hospitalization-time during consolidation in these patients. Thirty nine elderly patients with de novo AML (median age 69.9 years) who achieved complete remission (CR) after induction-chemotherapy were analyzed. To examine the effect of pegfilgrastim on neutropenia and hospitalization, we compared cycles 2 and 4 where pegfilgrastim was given routinely from day 6 (IDAC-P) with cycle 3 where pegfilgrastim was only administered in case of severe infections and/or prolonged neutropenia. All four planned cycles were administered in 23/39 patients (59.0%); 5/39 patients (12.8%) received 3 cycles, 3/39 (7.7%) 2 cycles, and 8/39 (20.5%) one consolidation-cycle. The median duration of severe neutropenia was 7 days in cycle 2 (IDAC-P), 11.5 days in cycle 3 (IDAC), and 7.5 days in cycle 4 (IDAC-P) (P < .05). Median overall survival was 1.1 years and differed significantly between patients aged <75 and 75 years (P < .05). The probability to be alive after 5 years was 32%. Together, intensified consolidation can be administered in AML patients 60, and those who are <75 may benefit from this therapy. Routine administration of pegfilgrastim during consolidation shortens the time of neutropenia and hospitalization in these patients.
| I N T R O D U C T I O N
More than 50% of all AML patients are over 60 years at diagnosis. [1] [2] [3] [4] [5] [6] [7] [8] [9] In a considerable number of these patients, the poor performance status or/and co-morbidities prohibit intensive myelosuppressive therapy. [4] [5] [6] [7] [8] [9] Most induction regimens that have been employed in elderly AML patients are the same as those applied in younger adults. 1, 2, [8] [9] [10] [11] [12] However, the efficacy is poor in the elderly compared to younger patients. This appears to be due to a relatively high rate of treatment-related deaths as well as poor prognostic features. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] It is generally appreciated that intensive post-remission therapy is of importance to maintain remission in patients with AML. [13] [14] [15] In younger patients, high-dose chemotherapy and/or allogeneic stem cell transplantation (HSCT) are established approaches. [16] [17] [18] [19] [20] [21] In patients aged 60 years, however, the consolidation strategies are discussed controversially. In many studies, post-remission treatment consists only of 1 to 2 cycles of intermediate dose chemotherapy. [9] [10] [11] [12] Only a few studies used repetitive cycles of high dose consolidation chemotherapy in elderly AML patients. 22, 23 Therefore, one reason for the unfavorable survival in elderly AML patients compared to younger adults may be the relatively low dose of chemotherapy applied during consolidation.
In this regard, one unresolved question is what age might be considered as an absolute upper limit to consider an intensive cytotoxic consolidation therapy. For example, high dose ARA-C may cause neurotoxicity in elderly patients with AML. 24 In a previous study we have shown that repetitive cycles of intermediate dose ARA-C employing 1 g/m 2 on days 1, 3, and 5 (up to four cycles) is an effective and well-tolerated consolidation in patients aged 60. 22, 23 However, although the phase of neutropenia was relatively short in these patients, neutropenic fever and severe infections were still recorded. 22, 23 Granulocyte colony-stimulating growth factor (G-CSF), a major regulator of neutrophil development and function, has been described to reduce the duration of chemotherapy-induced neutropenia and to prevent associated complications in AML patients. [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] The use of G-CSF (filgrastim) is safe and is not affecting the CR rate or duration of CR. [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] These studies have also shown that the time to neutrophil recovery is significantly shorter in AML patients receiving G-CSF compared to control patients without G-CSF support. [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] With regard to the duration of hospitalization the data are conflicting. Some studies showed a significant shortening of the duration of hospitalization whereas other studies were unable to confirm these results. 26, 27, [29] [30] [31] [32] [33] In most clinical trials, G-CSF was administered shortly after induction chemotherapy. However, only a few studies have examined the effects of G-CSF during consolidation therapy. 35 In contrast to filgrastim, pegfilgrastim has to be administered only once per chemotherapy cycle since neutrophils are the exclusive site of pegfilgrastim clearance.
The aim of the present study were to evaluate the efficacy and feasibility of intensified consolidation elderly patients with de novo AML and to define the effect of pegfilgrastim on neutropenia and hospitalization in these patients.
| S U B JE C T S A ND M E T HOD S

| Patients
Patients with de novo AML aged 60 years (n 5 64) were included in 
| Examinations at diagnosis and during follow up
Before and during each induction and consolidation cycle, starting at the day before chemotherapy until neutrophil recovery (absolute neutrophil [36] [37] [38] Results from molecular studies examining FLT3
ITD mutations, NPM1 mutations (NPM1-mut), and the KIT mutation D816V as well as multiplex PCR studies examining AML/ETO, CBFa/ MYH11, and MLL1-AF10 were available in a subset of patients (Supporting Information Table S2 ). The median age of the 39 patients eligible for consolidation was 69.9 years, ranging from 60 to 78 years (<75 years, n 5 34; 75 years, n 5 5; f:m-ratio, 1:1.6).
| Outcome of induction therapy
Of the 64 patients included in this trial, two patients were withdrawn during the first induction cycle because of prolonged aplasia (>40 days) and refractory thrombocytopenia resulting in a subdural hematoma in one patient. Following the induction phase, 43 patients (68%) entered complete remission (CR), 33 after 1 cycle (DAV), 9 after 2 cycles (DAV and MiDAC light), and 1 patient after 3 cycles (DAV, MiDAC-light, and FLAG) of induction therapy. In 16 patients no remission (NR) was achieved. Of these patients, 7 received one induction cycle, 3 two cycles, and 6 three cycles. Three patients died because of infections.
| Number of consolidation cycles
In 39/43 CR patients (91%), consolidation therapy could be initiated. In 4 patients no consolidation therapy could be given according to the study protocol. In these patients, an early relapse (n 5 1), death due to a spontaneous pulmonary bleeding (n 5 1), a severe protocol violation (n 5 1), or aggravation of dementia (n 5 1) was found. All 4 planned courses of consolidation were administered in 23/39 patients (59.0%). Five patients (12.8%) received three, and 3 patients (7.7%) two cycles. In 8 patients (20.5%), the treatment had to be stopped after the 1st consolidation.
Causes to withhold further therapy are shown in 0-27 days). The median number of packed red cell and platelet concentrates given per consolidation cycle were 4 (range: 0-15) and 3 (range 0-13), respectively (Supporting Information Table S3 ).
| Tolerability and safety of intensified consolidation
Severe, life-threatening adverse events occurred in seven patients. There were two cases (aged 66 and 65) with a single severe adverse event, i.e., severe vomiting and nausea in consolidation 2, severe neutropenic fever in consolidation 2, and one case (aged 68) with 2 severe events, i.e., ARA-C-induced fever and neutropenic fever in consolidation 3. One patient (aged 73) developed a severe infection with hypotension and neurologic deterioration after the first consolidation and died later despite hematopoietic recovery from a cardiac arrest. In another patient (aged 76) severe neutropenic fever occurred during consolidations 1 and 4. In the 4th consolidation cycle this patient also developed pneumonia and died from septic shock. There was one case aged 76 years with cholecystitis and ileus during the 1st consolidation and severe emesis in the 2nd cycle. In the follow up, after complete recovery he developed a fatal spontaneous intracerebral bleeding. In another patient (aged 68) severe diarrhea developed during the 1st consolidation. In the follow up this patient developed pulmonary inflammation resulting in a fatal alveolar damage. With regard to the laboratory results, liver toxicity grades II, III, and IV were found in 10 patients, 2 patients, and 2 patients respectively.
Three patients had a grade II nephrotoxicity, but there were no cases of grade III or IV nephrotoxicity observed during consolidation therapy (Supporting Information Figure S1 ).
| OS and prognostic variables predicting OS
The median observation time was 1 year; 13 patients were followed for more than 4 years and 6 patients for more than 5 years. The 
HSCT, hematopoietic stem cell transplantation.
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median OS was 1.1 years and the probability to be alive 2 and 5 years after the start of therapy was 39% and 32%, respectively ( Figure 1A ).
Three patients, who received an allogeneic HSCT were included. One of these patients was in the consolidation arm and was transplanted after consolidation 1 (OS: 1 year), in two patients the HSCT was performed as salvage therapy because of blast cell persistence following the second induction cycle (OS: 1.2 and 0.5 years, respectively). Major differences in OS were observed when comparing patients aged <75 years with patients 75 years. The probability of survival after 2 and 5 years was 44% and 39% in the group aged <75 years, respectively. By contrast, in the cohort aged 75 years (n 5 11), only one patient was alive after 2 years, and no patient was alive after 5 years ( Figure 1A , P < .05). Marked differences were observed between NPM1-wild type (NPM1-wt) and NPM1-mut patient, between patients carrying a FLT3 ITD mutation and FLT3 ITD negative patient but not between female and male patients (Supporting Information Figure S2A ). All long-term survivors received at least three cycles of consolidation therapy (Supporting Information Figure S2B ).
| Continuous complete remission (CCR) and disease-free survival (DFS)
CCR and DFS, calculated in patients receiving at least 1 cycle of consolidation chemotherapy, were 1.25 years and 1.23 years, respectively (including one patient that underwent HSCT). The probability to be in CCR and DFS after 2 years was 37% and 35% respectively, and the probability to be alive 5 years after the start of therapy was 29% and 23%, respectively. Figure   S3 ). Karyotyping results were available in 32/39 patients. Significant differences were observed in CCR and DFS between patients in different ELN risk groups (Supporting Information Table S5 ; Figure S4A , B). In addition, CCR and DFS differed between patients receiving at least 3 consolidation cycles and those receiving less than 3 consolidation cycles (Supporting Information Figure S4C,D) . Finally, CCR and DFS differed among patients with NPM1-wt and NPM1-mut, and between FLT3 ITD-positive patients and FLT3 ITD-negative patients (Supporting Information Table S5 ).
| G-CSF shortens the duration of aplasia and hospitalization
To evaluate the effect of pegfilgrastim on the duration of neutropenia and hospitalization during consolidation, we compared the consolidation cycles where G-CSF was given routinely on day 6 (IDAC-P: cycles 2 and 4) with cycle 3 where G-CSF was only given based on ASCO criteria (IDAC). 42 Only patients who received all 4 planned cycles of 
| Serum levels of G-CSF during therapy
To evaluate how long plasma levels of pegfilgrastim were detectable after injection, the concentration of G-CSF was measured serially in 18 consolidation cycles (FLAG, n 5 16; IDAC, n 5 2). These measurements were done after administration of pegfilgrastim, i.e., between days 11 and 35 after start of chemotherapy. G-CSF was detectable in all serum samples taken before day 21 of chemotherapy, i.e., day 16 after the administration of pegfilgrastim. Thereafter, the number of samples with detectable G-CSF decreased. Thelatest serum samples with a detectable cytokine level were taken on day 27 of chemotherapy, i.e., day 22 after pegfilgrastim administration. There was a clear (inverse) correlation between G-CSF levels and the peripheral WBC. In patients with an early increase of WBC and granulocyte counts, there was an early decrease of G-CSF and vice versa (Figure 3) . More than 50% of all AML patients are 60 years or beyond at diagnosis. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [43] [44] [45] [46] In contrast to younger patients, elderly patients with AML may not always benefit from intensive chemotherapy. In our study 68% of all patients aged 60 achieved a CR. Of these, 91% were eligible for intensive consolidation. Although hematologic and nonhematologic toxicity were moderate, four patients died during consolidation. No severe grade III or IV nephrotoxicity or neurotoxicity was recorded and there was only one patient with grade III and grade IV liver toxicity, each. The probability to be alive after 5 years was 32%.
Patients aged <75 years showed a clearly better survival compared to those aged 75 years. Finally, our study also shows that the addition of pegfilgrastim during consolidation significantly shortens the duration of neutropenia and the duration of hospitalization.
The appropriate consolidation in AML patients aged 60 years who achieve a CR is still a matter of discussion. Many centers offer HSCT to a subset of (fit) elderly high risk AML patients. 19, 20, 47 Contrasting this strategy, other centers offer only a few cycles of low dose chemotherapy as consolidation. 13, 48 Overall, the optimal type and opti- Information Table S6 ). 22, 23 In the current study, FLAG was used as consolidation 1 instead of IDAC. This represents an intensification of consolidation chemotherapy and our data are the first to prove that such intensified consolidation therapy can be administered safely in patients aged 60 years. However, there were 7 cases of severe or life-threatening events resulting in 4 deaths during consolidation. This early death rate is within the range of published results 11, 22, 23 but is still lower compared to that seen in patients undergoing HSCT. 18, 19 However, considering the high rate of relapses in these patients, there is a need to introduce high-risk post CR therapies, such as high-dose consolidation or allogeneic HSCT.
Another strategy is to apply post-consolidation maintenance therapy. 49, 50 Considering the toxicity of our treatment approach, it is important to define predictive factors indicating which patients will benefit from such intensive treatment. One important risk factor is age. In fact, most results argue against intensive consolidation in these patients. Thus, in line with published results, age and performance status were the most important predictive factors to decide which patients might be eligible for and can benefit from intensive chemotherapy. 23, 45, 46 The karyotype is another well-established prognostic variable. The prognostic importance of karyotyping has been demonstrated in various studies. [37] [38] [39] 51 Similarly, in our study cohort, patients with a monosomal karyotype had the worst outcome.
In patients with intensive chemotherapy the long duration of neutropenia results in prolonged hospitalization and a high risk of neutropenic infections. It is generally accepted that the time of neutropenia can be shortened by application of G-CSF. [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] However, whether G-CSF therapy also results in a shorter time of hospitalization in AML patients is discussed controversially. 26, 27, [29] [30] [31] [32] [33] Moreover, with regard to the application of G-CSF during consolidation only limited data are available. 26, 52, 53 We compared the duration of hospitalization and absolute neutropenia in the 2nd, 3rd, and 4th consolidation cycles.
There was a significant difference in the duration of neutropenia and duration of hospitalization between the 2nd and 3rd consolidation cycles as well as between the 3rd and 4th consolidation cycles although 18% of the patients had received G-CSF during the 3rd cycle according to ASCO criteria. 42 These data strongly suggest that the administration of pegylated G-CSF shortens not only the duration of neutropenia but also the duration of hospitalization during consolidation in elderly AML patients.
Whereas G-CSF has to be administered every day due to its short half-life, pegylated G-SCF (pegfilgrastim) has the same efficacy as filgrastim, but a reduced renal clearance. 35 Neutrophil-mediated clearance is the major mechanism of drug-elimination in these patients. 35 We were therefore interested to see how long plasma levels of pegfilgrastim were detectable after therapy. This was of particular interest since after the start of consolidation almost normal granulocyte counts were detectable up to day 10 or day 11. Pegfilgrastim was detectable throughout the observation period until full neutrophil recovery. There was decrease of pegfilgrastim between day 6 and 12 after administration (i.e., day 12 and 18 of chemotherapy). This could be an effect of remaining granulocytes. However, it is also tempting to speculate, that this could be a sign of early regrowth of neutrophil precursors.
Whether a delayed administration of pegfilgrastim would improve the efficacy remains to be elucidated. Overall, our data are in line with those that demonstrate the long-term effect of pegfilgrastim on neutrophil recovery during repetitive cycles of consolidation therapy in AML in younger patients. 54 Together, our data show, that intensified consolidation chemotherapy can be administered safely in AML patients aged 60 years and results in an improved survival. A majority of patients received all 4 consolidation cycles although substantial toxicity was observed. Unfavorable factors concerning survival were age 75 years and monosomal karyotype. Thus, our data suggest that a subset of elderly patients with AML, aged 60-74, benefit from intensified consolidation therapy. The administration of pegfilgrastim during consolidation shortened not only the duration of neutropenia but also the time of hospitalization.
Therefore, it seems reasonable to argue that both filgrastim and pegfilgrastim can be regarded as standard adjunct to consolidation therapy of elderly patients with AML.
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